INDICATION(S)
The cabazitaxel and prednisone regimen ( Table 1 ) has been studied and is recommended for metastatic, castration-resistant prostate cancer progressing after docetaxel treatment. [1] [2] [3] [4] [5] [6] 
DRUG PREPARATION
Follow institutional policies for preparation of hazardous medications when preparing cabazitaxel. A. Cabazitaxel 7, 8 1. Use cabazitaxel 60 mg/1.5 mL for reconstitution. 2. Dilute cabazitaxel with the provided 13% (w/w) ethanol in water to a final concentration of 10 mg/mL. 3. Both the cabazitaxel vial and the diluent vial contain overfill to make up for liquid loss in preparation. 4. Dilution of the cabazitaxel vial with the entire contents of the diluent vial produces a solution of 10 mg/mL of cabazitaxel. 
SUPPORTIVE CARE
A. Acute Emesis Prophylaxis: The cabazitaxel and prednisone regimen is predicted to cause vomiting in 10% to 30% of patients. 9 The studies reviewed reported nausea in 22% to 34% 1,3 and vomiting in 15% to 23% of patients. 1, 3 Appropriate acute emesis prophylaxis includes a serotonin antagonist or corticosteroid or dopamine antagonist. 9,10 One of the following regimens is suggested 9,10 : 1. Ondansetron 16 to 24 mg orally (PO), or granisetron 2 mg PO, or dolasetron 100 mg PO, or palonesetron 0.25 mg IV 30 minutes before cabazitaxel, or 2. Dexamethasone 12 to 20 mg PO 30 minutes before cabazitaxel, or 3. Metoclopramide 10 to 40 mg PO or prochlorperazine 10 mg PO 30 minutes before cabazitaxel.
B. Breakthrough Nausea and Vomiting: Patients
should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is suggested 9,10 : 
C. Hematopoietic Growth Factors:
Accepted practice guidelines and pharmaco economic analysis suggest that antineoplastic regimens have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 11 In the trials reviewed, neutropenia was reported in 20% to 94% 1,3 of patients and grade 3 to 4 neutropenia in 7% to 82% 1-3 of patients. Febrile neutropenia was reported in 2% to 8% of patients. [1] [2] [3] Prophylactic use of CSFs is not recommended with this regimen. CSFs should be considered if a patient experiences febrile neutropenia or grade 4 neutropenia in a prior cycle of cabazitaxel and prednisone. D. Hypersensitivity Reactions: Cabezitaxel contains polysorbate 80, a solubilizing agent known to cause severe non-immunologic anaphylactoid reactions. 12 The studies reviewed did not report hypersensitivity reactions with cabazitaxel, [1] [2] [3] [4] [5] possibly due to the small amount of polysorbate 80 contained in the US Food and Drug Administration (FDA)-approved dose of cabazitaxel. 1, 7, 8, 13 The manufacturer of cabazitaxel warns that severe hypersensitivity may occur and may include generalized rash/erythema, hypotension, and bronchospasm. 8 The following premedication regimen is recommended, all given intravenously 30 minutes before cabazitaxel 1,7,8,13 : 1. Cabazitaxel 10 mg/m 2 IV weekly and prednisone 5 mg twice daily. 4 2. Cabazitaxel 16 mg/m 2 IV days 1 and 15 and prednisone 10 mg PO daily, cycle repeats every 4 weeks. 5 An equivalent dose of prednisolone was allowed if prednisone was not available. [1] [2] [3] Note: IV = intravenous; PO = oral.
1. Dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent antihistamine, and 2. Dexamethasone 8 mg or equivalent corticosteroid, and 3. Ranitidine 50 mg, or equivalent H 2 antagonist.
MAJOR TOXICITIES
Most of the toxicities listed below are presented according to their degree of severity. Higher grades represent more severe toxicities. Although there are several grading systems for cancer chemotherapy toxicities, all are similar. One of the frequently used systems is the National Cancer Institute Common Terminology Criteria for Adverse Events (http://evs. nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf). Oncologists generally do not adjust doses or change therapy for grade 1 or 2 toxicities; but they make, or consider making, dosage reductions or therapy changes for grade 3 or 4 toxicities. Incidence values are rounded to the nearest whole percent unless incidence was less than or equal to 0.5%. A. Cardiovascular: Myocardial infarction (grade 3 or 4) 1%, 2 
C. Recommended Pretreatment Values:
The minimally acceptable pretreatment values required to begin a cycle with full-dose therapy were absolute neutrophil count (ANC) of 1,500 cells/mcL, 3, 8 platelet count of 100,000 cells/mcL, 3 hemoglobin of 10 g/dL, 3 serum bilirubin less than upper limit of normal (ULN), 3, 8 AST and ALT less than 1.5 times ULN, 3, 8 creatinine clearance greater than 30 mL/min, 8, 14 and serum creatinine less than 1.5 times ULN or creatinine clearance greater than 60 mL/min if serum creatinine was ULN to 1.5 times ULN. 3
DOSAGE MODIFICATIONS
A. Renal Function 1. Cabazitaxel: Use with caution in patients with creatinine clearance less than 30 mL/min. 8,14 2. Prednisone: No adjustment required.
